Recombinant interleukin-12 and interleukin-18 antitumor therapy in a guinea-pig hepatoma cell implant model

Cancer Science

Volumn 98, Issue 12, 2007, Pages 1936-1942

  Shiratori, Ikuo ^a,b,g   Suzuki, Yasuhiko ^c   Oshiumi, Hiroyuki ^d   Begum, Nasim A ^a,h   Ebihara, Takashi ^d   Matsumoto, Misako ^a,b,d   Hazeki, Kaoru ^e   Kodama, Ken ^a   Kashiwazaki, Yasuo ^f   Seya, Tsukasa ^a,d  

^a Osaka Medical Center for Cancer   (Japan)

^b NARA INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e HIROSHIMA UNIVERSITY   (Japan)

^f Drug Research Division   (Japan)

^g TOKYO UNIVERSITY OF SCIENCE   (Japan)

^h KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 18;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER TRANSPLANTATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG POTENTIATION; GUINEA PIG; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; LIVER CELL CARCINOMA; LIVER INJURY; LOW DRUG DOSE; LYMPH NODE METASTASIS; MONOTHERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; GUINEA PIGS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-12; INTERLEUKIN-18; LIVER NEOPLASMS; RECOMBINANT PROTEINS; TOLL-LIKE RECEPTORS;

EID: 35548946542     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00614.x     Document Type: Article

References (42)

1. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Iimunol 2003; 3: 133-46.
2. Steinman RM, Hemmi H. Dendritic cells: Translating innate to adaptive immunity. Curr Top Microbiol Immunol 2006; 311: 17-58.
3. Tahara H, Lotze MT. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther 1995; 2: 96-106.
4. Coughlin CM, Salhany KE, Gee MS et al. Tumor cell responses to IFNγ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 1998; 9: 25-34.
5. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996; 87: 3877-82.
6. Okamura H, Tsutsi H, Komatsu T et al. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 1995; 378: 88-91.
7. Coughlin CM, Salhany KE, Wysocka M et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 1998; 101: 1441-52.
8. Osaki T, Peron JM, Cai Q et al. IFN-γ-inducing factor/IL-18 administration mediates IFN-γ- and IL-12-independent antitumor effects. J Immunol 1998; 160: 1742-9.
9. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-76.
10. Tsuji S, Matsumoto M, Takeuchi O et al. Maturation of human dendritic cells by cell-wall skeleton of Mycobacterium bovis Bacillus Calmette-Guerin: Involvement of Toll-like receptors. Infect Immun 2000; 68: 6883-90.
11. Akazawa T, Ebihara T, Okuno M et al. Antitumor NK activation induced by the Toll-like receptor3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc Natl Acad Sci USA 2007; 104: 252-7.
12. Kodama K, Higashiyama T, Takami S, Imaoka S. BCG-CWS immunotherapy: A five year survival report. Jpn J Clin Oncol 2007; (in press).
13. Lacour J, Lacour F, Spira A et al. Adjuvant treatment with polyadenylic-polyuridylic acid (Polya: Polyu) in operable breast cancer. Lancet 1980; 2: 161-4.
14. Hayashi A, Noda A. Does the cell wall skeleton from Bacille Calmette-Guerin directly induce interferon-γ, independent of interleukin-12? Jpn J Clin Oncol 1996; 26: 124-7.
15. Scarim AL, Arnush M, Blair LA et al. Mechanisms of beta-cell death in response to double-stranded (ds) RNA and interferon-gamma: dsRNA-dependent protein kinase apoptosis and nitric oxide-dependent necrosis. Am J Pathol 2001; 159: 273-83.
16. Akazawa T, Masuda H, Saeki Y et al. Adjuvant-mediated tumor regression and tumor-specific CTL induction are impaired in MyD88-deficient mice. Cancer Res 2004; 64: 757-64.
17. Saiki I, Kamisango K, Tanio Y, Okumura H, Yamamura Y, Azuma I. Adjuvant activity of purified peptidoglycan of Listeria monocytogenes in mice and guinea pigs. Infect Immun 1982; 38: 58-65.
18. Cohen J. IL-12 deaths: Explanation and a puzzle. Science 1995; 270: 908.
19. Motzer RJ, Rakhit A, Schwartz LH et al. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 1998; 4: 1183-91.
20. Motzer RJ, Rakhit A, Thompson JA et al. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-α2a for patients with advanced renal cell carcinoma. J Interferon Cytokine Res 2001; 21: 257-63.
21. Shiratori I, Matsumoto M, Tsuji S, Nomura M, Toyoshima K, Seya T. Molecular cloning and functional characterization of guinea pig IL-12. Int Immunol 2001; 13: 1129-39.
22. Lieschke GJ, Rao PK, Gately MK, Mulligan RC. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nat Biotechnol 1997; 15: 35-40.
23. Inoue N, Fukui A, Nomura M et al. A novel chicken membrane-associated complement regulatory protein: Molecular cloning and functional characterization. J Immunol 2001; 166: 424-31.
24. Kikkawa S, Matsumoto M, Shida K, Toyoshima K, Seya T. Human macrophages produce dimeric forms of IL-18 which can be detected with monoclonal antibodies specific for inactive IL-18. Biochem Biophys Res Commun 2001; 281: 461-7.
25. Shida K, Shiratori I, Matsumoto M et al. An alternative form of IL-18 in human blood plasma: Complex formation with IgM defined by monoclonal antibodies. J Immunol 2001; 166: 6671-9.
26. Zwilling BS, Aldrich WA, Rinehart JJ. Induction of lymphokine-activated killer cells in strain 2 guinea pigs with human interleukin-2. Cancer Res 1986; 46: 5667-70.
27. Kataoka T, Yamamoto S, Yamamoto T, Tokunaga T. Immunotherapeutic potential in guinea-pig tumor model of deoxyribonucleic acid from Mycobacterium bovis BCG complexed with poly- l -lysine and carboxymethylcellulose. Jpn J Med Sci Biol 1990; 43: 171-82.
28. Hashimoto W, Osaki T, Okamura H et al. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J Immunol 1999; 163: 583-9.
29. Tanaka F, Hashimoto W, Okamura H, Robbins PD, Lotze MT, Tahara H. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells. Cancer Res 2000; 60: 4838-44.
30. Pardoll DM. T cells and tumours. Nature 2001; 411: 1010-12.
31. Hiromatsu K, Dascher CC, Sugita M et al. Characterization of guinea-pig group 1 CD1 proteins. Immunology 2002; 106: 159-72.
32. Kato H, Takeuchi O, Sato S et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006; 441: 101-5.
33. Yamamoto T, Jeevan A, Ohishi K et al. A new assay system for guinea pig interferon biological activity. J Interferon Cytokine Res 2002; 22: 793-7.
34. Graur D, Hide WA, Li WH. Is the guinea-pig a rodent? Nature 1991; 351: 649-52.
35. D'Erchia AM, Gissi C, Pesole G, Saccone C, Arnason U. The guinea-pig is not a rodent. Nature 1996; 381: 597-600.
36. Dascher CC, Hiromatsu K, Porcelli SA, Brenner MB, LeClair KP. Conservation of a CD1 multigene family in the guinea pig. J Immunol 1999; 163: 5478-88.
37. Hiromatsu K, Dascher CC, LeClair KP, Sugita M, Brenner MB, Porcelli SA. Induction of CD1-restricted immune responses in guinea pigs by immunization with mycobacterial lipid antigens. J Immunol 2002; 169: 330-9.
38. Parham C, Chirica M, Timans J, Vaisberg E, Moore KW. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002; 168: 5699-708.
39. Oppmann B, Lesley R, Blom B, Bazan JF, Kastelein RA. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2002; 13: 715-25.
40. + T cells. Immunity 2002; 16: 779-90.
41. Devergne O, Birkenbach M, Kieff E. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci USA 1997; 94: 12 041-6.
42. Belladonna ML, Renauld JC, Bianchi R et al. IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J Immunol 2002; 168: 5448-54.